NASDAQ · MOVE
Corvex, Inc.
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
Loading market information…
NASDAQ · IMCC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
IM Cannabis Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IM Cannabis Corp.’s next earnings report is currently expected on Nov 16, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IM Cannabis Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand. Furthermore, it supplies dried flower, pre-rolled products, and compressed hashish via its WAGNERS and Highland Grow labels. IM Cannabis Corp. serves a broad customer base, addressing the needs of both medical patients and adult recreational consumers. Its corporate headquarters are located in Tel Aviv-Yafo, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 31, 2025 | -$6.69+42.81% vs estimate | $9.27M-7.89% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | -$0.29+99.05% vs estimate | $9.91M-11.69% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
$5.23-$0.01 (-0.19%)
Shuttle Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.22% below the high.
$4.88+$0.14 (+2.95%)
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$7.79-$3.69 (-32.14%)
Flora Growth Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.43% below the high.
$1.57-$0.06 (-3.38%)
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
$1.10+$0.03 (+2.8%)
Akanda Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.61% below the high.
$1.90+$0.02 (+1.06%)
NanoVibronix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.83% below the high.
